ARTICLE | Clinical News
AC2993 LAR: Began Phase I trial
April 2, 2001 7:00 AM UTC
Alkermes Inc. (ALKS), Cambridge, Mass. Amylin Pharmaceuticals Inc. (AMLN), San Diego, Calif. Product: AC2993 LAR Business: Metabolic, Drug delivery Therapeutic category: Metabolism Target: GLP-I re...